



FY 21 President’s Request for BA Appropriations for FDA, Compared with FY 19 and FY 20 Funding
 ANALYSIS as of February 20, 2020 COB—Subject to change.

Source: Budget Authority Crosswalk, “Subtotal, Salaries and Expenses Account,”
On page 22 at <https://www.fda.gov/media/135078/download>

Budget Line—BA only “Salary and Expenses”	FY 19	FY 20 Final	FY 21 President’s Request 2/10/20
Food	\$ 1.060 billion	\$1.089 billion	\$1.091 billion
Human Drugs	\$ 663 million	\$ 683 million	\$ 683 million
Biologics	\$ 240 million	\$ 252 million	\$ 252 million
Animal Drugs and Feeds	\$ 179 million	\$ 191 million	\$ 190 million
Devices/Rad Health	\$ 387 million	\$ 395 million	\$ 416 million
National Center Tox. Research	\$ 67 million	\$ 67 million	\$ 66 million
Office of the Commissioner	\$ 188 million	\$ 184 million	\$ 187 million
All rent items; WO consolidation	\$ 285 million	\$ 297 million	\$ 321 million
Budget Authority Total	\$ 3.069 billion	\$3.158 billion	\$3.206 billion

The President’s proposal is for a \$48 million increase in “Salary and Expenses” in the BA (taxpayer funded) appropriations.

- This is: \$2 million additional for food; \$21 million additional for devices; \$2 million additional for programs in the Commissioner’s office; and \$24 million in total rent items. Offsetting are: \$1 million decreases for animal drugs and the National Center for Toxicological Research.
- Some of the year-to-year variance may be due to rounding and not substantive.
- These are net numbers that do not reflect offsetting decreases and additions in program within each funding line.
- The Administration report of a \$24 million increase is based on net decreases in Building and Facilities and Cures monies, not S&E.

21st Century Cures/FDA Innovation Fund monies come from reductions in mandated spending; not included in BA appropriations totals. In FY 20, this added \$75 million to resources available to FDA for specified purposes. The comparable number in FY 21 is \$70 million, which is the amount authorized under the statute.

For more information, contact Steven Grossman, the Deputy Executive Director of the Alliance for a Stronger FDA:
sgrossman@strengthenfda.org or 301-539-9660